- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04891640
Biologisk minskning och fånga barns resultat och flare frekvens vid ungdoms spondyloartrit (BACK-OFF JSpA)
Biologisk minskning och fånga barns resultat och flare frekvens i Juvenil Spondyloartrit (BACK-OFF JSpA)
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 31 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This project is a prospective, 12-month (+/- 1 month) pragmatic randomized trial embedded within routine clinical care. Children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a TNFi for 6 months or longer will be eligible for enrollment. Children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of TNFi (arm 2), or stopping TNFi (arm 3). The recommended visit frequency is every 3 months (+/- 1 month) through the study endpoint at 12 months (+/- 1 month). After subjects have followed their treatment assignment for 12 months (+/- 1 month), those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. All participants will be monitored for 24 additional months for long-term outcomes after the intervention period.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85006
- Phoenix Children's
-
-
California
-
Los Angeles, California, Förenta staterna, 90027
- Children's Hospital Los Angeles
-
Palo Alto, California, Förenta staterna, 94304
- Stanford University
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Children's Hospital of Colorado
-
-
Delaware
-
Wilmington, Delaware, Förenta staterna, 19803
- Nemours Children's Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20010
- Children's National Health System
-
-
Florida
-
Orlando, Florida, Förenta staterna, 32827
- Nemours Children's Health
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Riley Hospital for Children at IU Health
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa Stead Family Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota Masonic Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64108
- Children's Mercy Hospital
-
St Louis, Missouri, Förenta staterna, 63110
- St. Louis Children's Hospital
-
-
New York
-
New York, New York, Förenta staterna, 10021
- Hospital for Special Surgery
-
Queens, New York, Förenta staterna, 11040
- Cohen Children's Medical Center
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44302
- Akron Children's Hospital
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, Förenta staterna, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97227
- Randall Children's Hospital at Legacy Emanuel
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Vanderbilt Children's Hospital
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75390
- UT Southwestern Medical Center
-
Houston, Texas, Förenta staterna, 77030
- Texas Children's Hospital - Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84113
- Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Seattle Children's Hospital
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1E8
- The Hospital for Sick Children
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Males or females age 8 to 21 years
-
Juvenile SpA diagnosis:
• Symptom onset before their 16th birthday:
o International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis enthesitis-related arthritis subtype
OR;
• Symptom onset before their 18th birthday:
o Pediatric Rheumatology International Trials Organization (PRINTO) revision of the ILAR criteria enthesitis spondylitis-related JIA
- Peripheral arthritis and enthesitis, or
- Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on imaging, or
- Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative.
- If peripheral arthritis is present, it should persist for at least 6 weeks.
-
Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, or TNFi biosimilar) at standard doses
-
Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician
-
English speaking or Spanish speaking
-
Subject's treating physician recommended that he/she is a good candidate to participate in the study, which may include a modified therapy
-
Interested and willing to de-escalate TNFi therapy
Exclusion Criteria:
1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: TNFi Standard Therapy
Continue fixed standard treatment (i.e., no change from current therapy) |
Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed. |
|
Experimentell: TNFi fixed longer dosing intervals
Fixed longer dosing intervals of TNFi (i.e., increased time between doses) |
Participants randomly assigned to this arm will increase the time between TNFi medication doses.
|
|
Experimentell: TNFi Therapy Withdrawal
Stop TNFi treatment |
Participants randomly assigned to this arm will stop TNFi medication. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Juvenile Spondyloarthritis (JSpA) flare
Tidsram: 12 months
|
JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in function is defined as ≥3 unit change in the PROMIS mobility or upper extremity T-scores. The Patient-Reported Outcomes Measurement Information System (PROMIS) short forms include 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation of 10. Active joint count is defined as the number of joints with swelling or, in the absence of swelling, limitation of motion accompanied by pain or warmth as per the physician examination. |
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pain interference (as measured by the PROMIS short form)
Tidsram: 12 months
|
Pain interference (as measured by the PROMIS short form) of children with spondyloarthritis in the three treatment arms. The PROMIS short form is a validated questionnaire that measures the self-reported consequences of pain on relevant aspects of a person's life.The PROMIS short form includes 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation equal to 10. |
12 months
|
Samarbetspartners och utredare
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 21-018442
- : GRT-00001036 (Annat bidrag/finansieringsnummer: PCORI)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .